Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
Junqing XieJames T BrashCigdem TurkmenStefan DriessenGiustino VarrassiGeorge ArgyriouSarah SeagerChristian ReichDaniel Prieto AlhambraPublished in: Drugs (2023)
In patients with osteoarthritis or back pain, we found no differential risks of incident COVID-19 diagnosis or COVID-19 hospitalisation for ibuprofen users compared with other ns-NSAIDs, COX-2i or paracetamol. Our findings support regulatory recommendations that NSAIDs, including ibuprofen, should be prescribed as indicated in the same way as before the COVID-19 pandemic, especially for those who rely on ibuprofen or NSAIDs to manage chronic arthritis or musculoskeletal pain symptoms.
Keyphrases
- anti inflammatory drugs
- coronavirus disease
- sars cov
- rheumatoid arthritis
- postoperative pain
- chronic pain
- respiratory syndrome coronavirus
- knee osteoarthritis
- cardiovascular disease
- pain management
- neuropathic pain
- risk assessment
- type diabetes
- zika virus
- depressive symptoms
- climate change
- spinal cord
- newly diagnosed
- human health
- dengue virus
- spinal cord injury
- drug induced